Skip header and navigation

12 records – page 1 of 1.

Adverse reactions between alcohol and drug products

https://policybase.cma.ca/en/permalink/policy805
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Less detail

Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/en/permalink/policy11514
Date
2015-Feb-28
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/en/permalink/policy11519
Date
2015-May-14
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

CMA Letter to the Senate Committee on Legal and Constitutional Affairs regarding Bill C-2, An Act to amend the Criminal Code and to make consequential amendments to other Acts

https://policybase.cma.ca/en/permalink/policy9110
Date
2008-Feb-19
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)

https://policybase.cma.ca/en/permalink/policy11599
Date
2015-Jun-08
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Complementary and alternative medicine (update 2015)

https://policybase.cma.ca/en/permalink/policy11529
Date
2015-May-30
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Drug product substitution

https://policybase.cma.ca/en/permalink/policy806
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Less detail

Equitable and comprehensive national pharmacare program

https://policybase.cma.ca/en/permalink/policy11652
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC15-72
The Canadian Medical Association supports the development of an equitable and comprehensive national pharmacare program.
Policy Type
Policy resolution
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC15-72
The Canadian Medical Association supports the development of an equitable and comprehensive national pharmacare program.
Less detail

Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/en/permalink/policy11535
Date
2015-May-30
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

National strategy on the use of naloxone

https://policybase.cma.ca/en/permalink/policy11651
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC15-71
The Canadian Medical Association supports the development and implementation of a national strategy on the use of naloxone.
Policy Type
Policy resolution
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC15-71
The Canadian Medical Association supports the development and implementation of a national strategy on the use of naloxone.
Less detail

Non-medicinal ingredients in drug products

https://policybase.cma.ca/en/permalink/policy802
Date
1985-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC85-28
The Canadian Medical Association calls on Health Canada to facilitate the dissemination of information to health professionals and consumers concerning the presence, in drug products, of non-medicinal ingredients that can cause adverse reactions.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
1985-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC85-28
The Canadian Medical Association calls on Health Canada to facilitate the dissemination of information to health professionals and consumers concerning the presence, in drug products, of non-medicinal ingredients that can cause adverse reactions.
Less detail

Price negotiations for prescription drugs

https://policybase.cma.ca/en/permalink/policy11649
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC15-69
The Canadian Medical Association urges the pan-Canadian Pharmaceutical Alliance to invite the federal government and private health insurance industry to participate in its price negotiations for prescription drugs.
Policy Type
Policy resolution
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC15-69
The Canadian Medical Association urges the pan-Canadian Pharmaceutical Alliance to invite the federal government and private health insurance industry to participate in its price negotiations for prescription drugs.
Less detail

12 records – page 1 of 1.